XBI · ARCA · ETF
State Street SPDR S&P Biotech ETF (XBI) Price, Holdings & Fees
State Street SPDR S&P Biotech ETF (XBI) closed at $644.79 on Oct 9, 2026, up 1.10% from the previous close of $637.76.
Share price, past year
1Y +17.38%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $644.79 |
| Sep 30, 2026 | $652.59 |
| Aug 31, 2026 | $666.11 |
| Jul 31, 2026 | $634.23 |
| Jun 30, 2026 | $604.93 |
| May 29, 2026 | $607.07 |
| Apr 30, 2026 | $597.88 |
| Mar 31, 2026 | $605.55 |
| Feb 27, 2026 | $594.53 |
| Jan 30, 2026 | $549.76 |
| Dec 31, 2025 | $536.04 |
| Nov 28, 2025 | $538.20 |
| Oct 31, 2025 | $551.92 |
Key statistics
- Expense ratio
- 0.35%
- as of Jun 30, 2025
- Net assets
- $10.7B
- as of Jun 30, 2026
- Holdings
- 161
- as of Jun 30, 2026
- 52-week range
- $522.72 – $667.99
State Street SPDR S&P Biotech ETF's expense ratio is 0.35%: $35.00 a year on $10,000 invested.
Holdings
State Street SPDR S&P Biotech ETF held 161 investments worth $10.73B as of Jun 30, 2026. Its largest holding was State Street Global Advisors, at 5.87% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | State Street Global Advisors | 5.87% | $630.64M |
| 2 | Apogee Therapeutics Inc | 1.49% | $159.76M |
| 3 | Moderna Inc | 1.41% | $151.61M |
| 4 | Twist Bioscience Corp | 1.41% | $151.14M |
| 5 | Oruka Therapeutics Inc | 1.38% | $147.99M |
| 6 | Kymera Therapeutics Inc | 1.36% | $145.95M |
| 7 | Viking Therapeutics Inc | 1.30% | $139.97M |
| 8 | Praxis Precision Medicines Inc | 1.29% | $138.52M |
| 9 | Erasca Inc | 1.27% | $136.43M |
| 10 | Revolution Medicines Inc | 1.20% | $129.32M |
| 11 | Rhythm Pharmaceuticals Inc | 1.20% | $128.98M |
| 12 | CG oncology Inc | 1.20% | $128.81M |
| 13 | SELLAS Life Sciences Group Inc | 1.19% | $127.74M |
| 14 | Vaxcyte Inc | 1.19% | $127.43M |
| 15 | Dianthus Therapeutics Inc | 1.18% | $127.01M |
| 16 | Cytokinetics Inc | 1.18% | $126.46M |
| 17 | Natera Inc | 1.16% | $124.85M |
| 18 | Scholar Rock Holding Corp | 1.16% | $124.20M |
| 19 | Roivant Sciences Ltd | 1.16% | $124.03M |
| 20 | Mirum Pharmaceuticals Inc | 1.16% | $124.00M |
| 21 | Cogent Biosciences Inc | 1.14% | $122.79M |
| 22 | Ultragenyx Pharmaceutical Inc | 1.14% | $122.44M |
| 23 | Travere Therapeutics Inc | 1.13% | $121.01M |
| 24 | Alkermes PLC | 1.11% | $119.00M |
| 25 | Krystal Biotech Inc | 1.10% | $118.47M |
Top 25 of 161 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 99.86% |
| Cash and short-term investments | 5.91% |
| Derivatives | 0.11% |
| Country | % of fund |
|---|---|
| United States | 100.75% |
| Ireland | 1.24% |
| Bermuda | 1.16% |
| Netherlands | 1.03% |
| Switzerland | 1.02% |
| British Virgin Islands | 0.53% |
| Canada | 0.16% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jun 30, 2026, State Street SPDR S&P Biotech ETF's total return was +24.02%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jun 30, 2026 | +15.80% |
| May 31, 2026 | +4.14% |
| Apr 30, 2026 | +2.84% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- State Street SPDR S&P Biotech ETF
- Ticker
- XBI
- Exchange
- ARCA
- Fund type
- ETF
- Trust
- SPDR SERIES TRUST
- SEC series ID
- S000010018
- SEC CIK
- 0001064642
- Fractional shares
- Yes
Recent SEC filings
- Aug 28, 2026
- Sep 4, 2026
- Sep 3, 2026
- 485BPOSProspectus updateAug 27, 2026
- Jul 2, 2026
- 485BPOSProspectus updateJun 23, 2026
- 485BPOSProspectus updateApr 24, 2026
- Mar 9, 2026
Shareholder reports and prospectuses are filed by SPDR SERIES TRUST, the trust behind State Street SPDR S&P Biotech ETF, and cover all of its funds.
Frequently asked questions
What is XBI's price?
State Street SPDR S&P Biotech ETF (XBI) closed at $644.79 on Oct 9, 2026, up 1.10% from the previous close of $637.76.
What is XBI's expense ratio?
State Street SPDR S&P Biotech ETF's expense ratio is 0.35%: $35.00 a year on $10,000 invested.
What does XBI hold?
State Street SPDR S&P Biotech ETF held 161 investments worth $10.73B as of Jun 30, 2026. Its largest holding was State Street Global Advisors, at 5.87% of the fund. Its five largest holdings were State Street Global Advisors, Apogee Therapeutics Inc, Moderna Inc, Twist Bioscience Corp, Oruka Therapeutics Inc.
How has XBI performed?
Over the 3 months to Jun 30, 2026, State Street SPDR S&P Biotech ETF's total return was +24.02%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 28, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jun 30, 2025. Prices are generated sample data for development. Data sources and disclosures